Jia Jie “Jennifer” Tang leverages her legal experience and expertise in biotechnology to counsel life sciences clients on intellectual property strategy and prosecute patents. This work includes conducting patent landscape searches and freedom-to-operate analyses.
Prior to joining MBHB, Jennifer was an Associate at Morgan Lewis & Bockius LLP, where she drafted and prosecuted patent applications focused on immunotherapies, antibodies, nucleic acid therapeutics, gene-editing technologies, and more.
J. J. Tang, et al. Natural Killer (NK) Cell Expression of CD2 as a Predictor of Serial Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC). Antibodies (Basel). 2020 Oct 16;9(4):54.
Co-author. An improved method to quantify human NK cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) per IgG FcR-positive NK cell without purification of NK cells. D J Immunol Methods. 2017 Nov 4. pii: S0022-1759(17)30429-5.
Co-author. Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) in Familial Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Fatigue. 2020;8(4):226-244.
Co-author. Inclusion of family members without ME/CFS in research studies promotes discovery of biomarkers specific for ME/CFS. Work. 2020;66(2):327-337.
